Meeting report: the Leprosy Research Initiative Spring Meeting

Autor: Veldhuijzen, N., Lenz, S.M., Collins, J.H., Ray, N.A., Deming, A.T., Lahiri, R., Adams, L.B., Hooij, A. van, Eeden, S. van den, Richardus, R., Wilson, L., Franken, K.L.M., Faber, R., Khatun, M., Alam, K., Richardus, J.H., Geluk, A., Balagon, M., Roferos, F., Abellana, J., Taborada, T., Sanchez, R., Maghanoy, A., Engelbrektsson, U.B., Magar, D.B., Sserunkuma, M.C., Moses, K., Ssembatya, B.B., LRI Scien Review Comm, LRI Steering Comm

Publikováno v: Leprosy Review, 90(2), 183-200

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::34a94f8278d7bdaaeeca8d1c23444290
https://hdl.handle.net/1887/120703

Understanding Basement Processes in Sub-Volcanic settings by Laboratory Measurements

Autor: Bakker, Richardus R.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90d5c7e59b1f706a9e553b3cb7a8150d

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Histology independent drug development - Is this the future for cancer drugs?

Autor: Billingham L; Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, UK. Electronic address: L.J.Billingham@bham.ac.uk., Brown L; Oncology Division, Merck & Co., Inc., Rahway, NJ, USA. Electronic address: lynn.may.brown@merck.com., Framke T; European Medicines Agency, Amsterdam, The Netherlands. Institute for Biostatistics, Hannover Medical School, Hannover, Germany. Electronic address: theodor.framke@ema.europa.eu., Greystoke A; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK. Electronic address: Alastair.greystoke@newcastle.ac.uk., Hovig E; Centre for Bioinformatics, University of Oslo, P.O. Box 1080 Blindern, 0316 OSLO, Norway; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, PO Box 4950 Nydalen, 0424 Oslo, Norway. Electronic address: ehovig@ifi.uio.no., Mathur S; Oncology Division, Merck & Co., Inc., Rahway, NJ, USA. Electronic address: siddhartha.mathur@merck.com., Page P; Human Colossus Foundation, Switzerland. Electronic address: philippe.page@humancolossus.org., Pean E; European Medicines Agency, Amsterdam, the Netherlands. Electronic address: elias.pean@ema.europa.eu., Barjesteh van Waalwijk van Doorn-Khosrovani S; National Funder's Committee for Evaluation of Specialised Medicines and Companion Diagnostics (CieBAG), the Netherlands; Department of Oncology, Leiden University Medical Centre The Netherlands CZ, Postbus 90152, 5000 LD, Tilburg, the Netherlands. Electronic address: sahar.van.waalwijk@cz.nl., Vonk R; Bayer AG 13342 Berlin, Germany. Electronic address: richardus.vonk@bayer.com., Wissink S; Merck Sharpe Dohme, the Netherlands. Electronic address: sacha.wissink@merck.com., Zander H; Paul-Elrich Institut, Germany. Electronic address: hilke.zander@pei.de., Plummer R; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK. Electronic address: ruth.plummer@ncl.ac.uk.

Publikováno v: Cancer treatment reviews [Cancer Treat Rev] 2024 Feb; Vol. 123, pp. 102674. Date of Electronic Publication: 2023 Dec 23.